Navigation Links
Lethality of H1N1 Influenza Virus Increasing According to Latest Analysis of Virus Peptide Genomic Data
Date:6/10/2009

Boston Biotech Firm Reports First Rise in 76 Years of Replikin Count* of H1N1 Lethality Gene

BOSTON, June 10 /PRNewswire/ -- An analysis of the latest peptide genomic data for the H1N1 influenza virus indicates that the current global outbreak of H1N1 is increasing in its capacity for lethality. The new sequence data on PubMed of the past two weeks through June 10, 2009 showed an increase in the Replikin Count* of the Replikin Lethality Gene in the pB1 genomic area from a mean of 2+/-0.2 in 2008 to a mean of 3.2+/-3.7 in 2009 (p<0.001). The Replikin Count of the Lethality Gene in 836 previous H1N1 influenza virus isolates has remained essentially unchanged (at 2) since 1933.

These analyses were conducted by the Boston-based biotech firm Replikins, Ltd. (http://www.replikins.com) using its FluForecast(R) software. A year ago (4/7/08), using the same software, the firm predicted the current H1N1 virus outbreak, and last month (5/23/09) an increase in the Replikin Count of the Replikin Infectivity Gene in the hemagglutinin area indicated a marked increase in infectivity of the evolving H1N1 virus.

"Last month the H1N1 genomic data indicated some bad and some good news. While it indicated an increase in the infectivity of the H1N1 virus, its lethality appeared to remain relatively low," noted Sam Bogoch, MD, PhD, chairman of Replikins Ltd. "However, the FluForecast(R) analysis of new data of the past few weeks, through June 10th, on 144 new specimens published on PubMed, indicate an increase in the current H1N1 outbreak's capacity for lethality. Since the software also permitted the automated analysis of all sequence data available on PubMed for all previous years, it was noted that this is the first such significant increase in the Replikin Count of the H1N1 Lethality Gene in 76 years. This is cause for concern and an accelerated vaccine effort."

For both the Infectivity Gene and the Lethality Gene, a significant increase in Replikin Count has invariably been followed by an increase in infectivity or lethality in influenza. While both the Replikin Infectivity Gene and the Replikin Lethality Gene have been found to act independently in all common influenza strains in human, swine, and bird hosts, both of these genes have been inhibited by the Two-Punch(TM) vaccine system -- designed to be concurrently directed at both genes.

The company recently announced that it has made available for testing against H1N1 a Two-Punch(TM) PanFlu(TM) vaccine. The same vaccine system has been successfully tested against H5N1 in chickens.

Chart: http://www.ereleases.com/pr/June10-Lethality-Graph.png

About Replikins, Ltd.

Replikins, LLC (http://www.replikins.com), a Boston-based biotech company, and Replikins, Ltd., develop and market novel forecasting tools and synthetic vaccines to fight virulent rapidly replicating diseases including bird flu, malaria, and HIV. The company's predictive products and vaccines in development are based upon the company's discovery of Replikins, a new group of peptides related to the rapid replication function in viral and other diseases. The company has designed unique products to predict the emergence of virulent strains of particular diseases (FluForecast(TM)) and is designing synthetic vaccines specifically tailored to combat a given strain and against shared properties of several strains (Syntope(TM) vaccines). The company is partnering with governments and the private sector in providing predictive tools and vaccines in furtherance of the public health initiative to prevent and combat epidemics.

* The company's vaccines and predictive tools are based on the company's discovery of a new group of peptides related to rapid replication called Replikins, whose increase in concentration in virus or other organism proteins (Replikin Count(TM) = number of replikins per 100 amino acids) is associated with rapid replication.

    Contact:

    John McKenney
    jmckenney@replikins.com
    617-536-0220

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Replikins Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Swine Flu (H1N1) Infectivity to Increase Markedly and Lethality to Remain Low According to Latest Replikin* Peptide Genomic Data
2. Sinovac Begins the Production of Influenza A (H1N1) Vaccine
3. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
4. HHS Awards MedImmune Contract to Manufacture Live Attenuated Nasal Spray Vaccine for Novel Influenza A (H1N1)
5. Sanofi Pasteur Receives Seed Virus to Produce New Influenza A(H1N1) Vaccine
6. Thomson Reuters Makes Disease Briefing on Influenza Covering H1N1 (Swine Flu) Publicly Available
7. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
8. Meso Scale Diagnostics Point of Care Influenza Test Led to the First Identification of A(H1N1) Swine Flu Infection
9. H1N1 Influenza "Swine Flu" Peptide Vaccine Now Available For Testing Worldwide
10. Germgards Ultra-Fast Hand Hygiene Solution Protects Against Deadly MRSA, C difficile, and Influenza Virus
11. CEL-SCIs L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... Nov. 30, 2016  The Allen Institute for ... the first publicly available collection of gene edited, ... target key cellular structures with unprecedented clarity. Distributed ... powerful tools are a crucial first step toward ... understand what makes human cells healthy and what ...
(Date:11/30/2016)... , Nov. 30, 2016  Tempus, a ... cancer care, and Penn,s Abramson Cancer Center have ... a positive response to immunotherapy treatment based on ... As part of a research collaboration, Tempus ... and melanoma cancer patient data to Penn. Utilizing ...
(Date:11/30/2016)... , 30. November 2016   Merck ... heute die Unterzeichnung einer Reihe von Vereinbarungen ... wird Evotec AG Screeningleistungen für Mercks Palette ... Der Zugriff auf diese Bibliotheken in Kombination ... einen schnelleren Weg zur Ermittlung und Erforschung ...
(Date:11/30/2016)... --  Merck , a leading science and technology company, ... of agreements with Evotec AG, whereby Evotec AG will ... such as CRISPR and shRNA libraries. Combining access to ... pathway to explore and identify new drug targets. ... targets, a process that can be time- and labor-intensive," ...
Breaking Biology Technology:
(Date:11/22/2016)... MINNETONKA, Minn. , Nov. 22, 2016   ... that supports the entire spectrum of clinical research, is ... by Medical LiveWire Healthcare and Life Sciences Awards ... This award caps off an unprecedented year of recognition ... clinical trials for over 15 years. iMedNet ...
(Date:11/16/2016)... , Nov. 16, 2016 Sensory Inc ... and security for consumer electronics, and VeriTran ... and retail industry, today announced a global partnership ... way to authenticate users of mobile banking and ... TrulySecure™ software which requires no specialized biometric ...
(Date:6/27/2016)... 27, 2016 Research and Markets has announced ... report to their offering. ... to grow at a CAGR of 12.28% during the ... on an in-depth market analysis with inputs from industry experts. The ... coming years. The report also includes a discussion of the key ...
Breaking Biology News(10 mins):